Olpasiran

Summary

Olpasiran (CHEMBL4650413) is a phase-3 clinical-stage oligonucleotide; indicated across 4 conditions including cardiovascular disorder and liver disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 4 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650413
Name	Olpasiran
Type	Oligonucleotide
Max phase	3

Also known as: Amg 890, AMG 890, AMG-890, Olpasiran, OLPASIRAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	3	MONDO:0004995	EFO:0000319
liver disorder	1	MONDO:0005154	EFO:0001421
kidney disorder	1	MONDO:0005240	EFO:0003086
atherosclerosis	1	MONDO:0005311	EFO:0003914

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	4
PHASE3	3
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05581303	PHASE3	ACTIVE_NOT_RECRUITING	Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
NCT07136012	PHASE3	RECRUITING	OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
NCT07293260	PHASE3	RECRUITING	Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT04270760	PHASE2	COMPLETED	Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
NCT04987320	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Olpasiran in Chinese Participants With Elevated Serum Lipoprotein(a)
NCT05481411	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
NCT05489614	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
NCT06411860	PHASE1	COMPLETED	A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
NCT07079267	Not specified	AVAILABLE	Olpasiran Expanded Access Program

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).